Amgen stated on Monday that it had reached an agreement in principle to settle both federal and state allegations of illegal marketing tactics.  The settlement is expected to resolve all criminal and civil allegations, including those brought by whistleblowers.  Amgen reserved $780 million for this settlement on Monday.

According to Amgen, the suits pertain to its marketing of Aranesp, an anemia drug.  Amgen reportedly overfilled vials of the drug and incentivized doctors to use its drug rather than its competitor’s by encouraging them to bill health insurance companies, including Medicare and Medicaid, for the additional amount.

This settlement comes just shortly after Amgen was to begin trial on these allegations–the date had been set for October 17th.

Read the entire article, “Amgen to Pay $780 Million to Settle Suits on Its Sales”